Eupraxia

Eupraxia emerged as one of three CROs in India to perform the Pre-Clinical Trial Data Analysis and SEND submission package and/or review of the same in India, Eupraxia has delivered 36+ Pre-Clinical Studies' USFDA SEND package creations involving Single Dose Toxicity, Repeat Dose Toxicities, Safety Pharmacology (Cardiovascular pharmacology and Resp... iratory pharmacology) and Carcinogenicity studies. Eupraxia has 6 clients to its credit in last 2 years. For Biotech companies, Eupraxia Modelling & Analytics team has developed predictive analysis models using biostatistics, fractals, Bayesian Network Algorithm and genetic algorithms. We have successfully delivered 5 studies in last 3 years. In January 2020, Eupraxia acquired a medical device consulting company and built a dedicated Medical Device CRO "Alceon" around it to conduct MedDevice Clinical Trials and MDR implementation for Europe. This strategic move was necessary to support small scale med-device manufacturers of the country to support them export their products to European markets. Eupraxia has invested and developed tools to support statistical genetics and proteomics, using R programming language platform. Very few government-funded institutions offer these services in India but not much heard of any CRO. We have first project awarded in November 2019 in this direction. Eupraxia has strategic alliance with Amsterdam-based health service consulting firm SparkHealth. As joint effort of this alliance, Eupraxia has developed specialization in Epidemiological Disease Modelling with first live on-going project with one of the districts of the State of Maharashtra on creating registry for COVID-19. The computational disease modelling SBU of Eupraxia and SparkHealth provide deeper insights in to the spatial progression of the disease so as to take administrative steps by the local and state governments to minimise/arrest the adverse impact of the disease. While Eupraxia and SparkHealth provide technical expertise, Castor EDC platform company has provided its ...Read More